Published in final edited form as:

Chembiochem. 2003 June 6; 4(6): 508–513. doi:10.1002/cbic.200300560.

Simplified Synthetic TMC-95A/B Analogues Retain the Potency of Proteasome Inhibitory Activity

Zhi-Qiang Yang^a, Benjamin H. B. Kwok^c, Songnian Lin^a, Michael A. Koldobskiy^c, Craig M. Crews^{c,d,e}, and Samuel J. Danishefsky^{a,b}

^aLaboratory of Bioorganic Chemistry, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York 10021 (USA), Fax: (+1) 212-772-8691

^bDepartment of Chemistry, Havemeyer Hall, Columbia University, New York 10027 (USA)

^cDepartment of Molecular, Cellular and Developmental Biology, Yale University, 219 Prospect Street, New Haven, CT 06520-8103 (USA)

^dDepartment of Pharmacology, Yale University, New Haven, CT 06520 (USA)

^eDepartment of Chemistry, Yale University, New Haven, CT 06520 (USA)

Abstract

The proteasome regulates diverse intracellular processes, including cell-cycle progression, antigen presentation, and inflammatory response. Selective inhibitors of the proteasome have great therapeutic potential for the treatment of cancer and inflammatory disorders. Natural cyclic peptides TMC-95A and B represent a new class of noncovalent, selective proteasome inhibitors. To explore the structure-activity relationship of this class of proteasome inhibitors, a series of TMC-95A/B analogues were prepared and analyzed. We found that the unique enamide functionality at the C-8 position of TMC-95s can be replaced with a simple allylamide. The asymmetric center at C-36 that distinguishes TMC-95A from TMC-95B but which necessitates a complicated separation of the two compounds can be eliminated. Therefore, these findings could lead to the development of more accessible simple analogues as potential therapeutic agents.

Keywords

inhibitors; peptides; proteasome; synthesis; structure-activity relationships

Introduction

In eukaryotic cells, proteins are degraded predominantly by the ubiquitin proteasome pathway. [1,2] The central enzyme of this process, the 26S proteasome, is a multicatalytic protease complex found in both the cytosol and the nucleus. In this pathway, targeted proteins are first marked by covalent attachment with a polyubiquitin chain.[3] The subsequent degradation by the proteasome requires adenosine triphosphate (ATP) hydrolysis, which indicates that the 26S proteasome is a eukaryotic ATP-dependent protease.[4,5] This enzyme consists of a 20S proteolytic core particle and a 19S regulatory subunit at either one or both ends.[6] The 19S complex is responsible for binding and removal of the ubiquitin chain and unfolding and translocation of the proteins to the 20S particle for degradation.[6] The 20S core complex is a barrel-shaped structure composed of four stacked multiprotein rings.[7,8,9] Each of the

two central β rings contains three active proteolytic sites that function together to hydrolyze the proteins into small peptides. These active sites differ in their specificities: one cleaves preferentially after hydrophobic residues, one after basic residues, and one after acidic residues. Accordingly, the sites are called chymotrypsin-like (CT-L), trypsin-like (TL), and postglutamyl peptide hydrolytic (PGPH) sites, respectively.[10–12] The proteolytic sites in the 20S proteasome function by utilizing an amino-terminal threonine of the β subunits as the catalytic nucleophile.[6]

The proteasome is not only responsible for the removal of damaged or misfolded proteins, but also for processing and degrading regulatory proteins that control many diverse cellular processes, including cell-cycle progression, apoptosis, and NF- κ B activation.[4,13] A small fraction of the peptides generated by the proteasome are presented by major histocompatibility complex class I molecules on the cell surface, and thus play a role in immune surveillance.[14–17] Therefore, inhibitors that selectively block proteolytic activities of the proteasome are of therapeutic potential for the treatment of cancer, inflammatory disorders, and immune diseases.[18–20] Many proteasome inhibitors have been developed, such as synthetic peptide aldehydes,[1] boronates,[21] or vinylsulfones,[22] as well as the natural products lactacystin [23] and epoxomicin.[24] All of these inhibitors function through covalent modification of the *N*-terminal threonine residue of β subunits.[18,19] Among them, PS-341,[25] a dipeptide boronate, has entered Phase II and Phase III trials as a drug against various cancers. Selective inhibitors of the proteasome show great promise as novel anticancer agents since tumor cells are more sensitive than normal cells to proteasome-inhibition-induced apoptosis.[26–28]

TMC-95A (**1**) and its diastereoisomers TMC-95B – D(**2** – **4**), recently isolated as fermentation products of *Apiospora montagnei*,[29] represent a new class of selective proteasome inhibitors (Scheme 1). These molecules are structurally characterized as novel cyclic peptides containing α -tyrosine, α -asparagine, highly oxidized α -tryptophan, (Z)-1-propenylamine (Z=benzyloxycarbonyl), and 3-methyl-2-oxopentanoic acid moieties.[30] Biological studies [29] showed that TMC-95A inhibited the CT-L, TL, and PGPH activities of 20S proteasome with IC₅₀ values (IC₅₀=concentration required for 50% inhibition) of 5.4, 200, and 60 nM, respectively. TMC-95B inhibited these activities to the same extent as TMC-95A, while TMC-95C and D were 20 – 150 times weaker inhibitors. TMC-95A did not inhibit m-calpain, cathepsin L, or trypsin at 30 μ M, which suggests it has high selectivity for the proteasome. The binding mode of these inhibitors has been recently elucidated by X-ray crystallography.[31] Unlike other proteasome inhibitors, TMC-95A does not modify the *N*-terminal catalytic threonine residue. It binds to all three active sites of the proteasome through characteristic hydrogen bonds. TMC-95A also has cytotoxic activity against human cancer cells HCT-116 and HL-60, with IC₅₀ values of 4.4 μ M and 9.8 μ M, respectively.[29]

The combination of structural novelty, potency, and the unique inhibition mechanism of TMC-95A and B led us to undertake a program of total synthesis directed towards this family of metabolites. Recently, our laboratory reported the first total synthesis of TMC-95A and B. [32] However, several structural features of these molecules have rendered our current synthesis impractical for producing amounts of materials appropriate for clinical follow-up. Besides a strained 17-membered heterocycle, whose efficient construction remains a challenge, these molecules also contain a rich diversity of vulnerable functionalities, particularly in the extended “pyruvoly”-like (C-34 – C-38) and dihydroxyindolinone (positions 22, 23, and 6 – 8) sections. A notable feature of the synthesis is the installation of the *cis*-enamide (C-25 – C-29) functionality by a novel rearrangement of α -silylallyl amide precursors (**10a,b** and **11 a,b**) at a very late stage (Scheme 2). As a result of the presence of sensitive groups on the molecules, multiple steps are required to execute the transformation of protected alcohol precursor **5** into the final targets (Scheme 2). We began to explore the structure-activity relationship of the proteasome inhibitors derived from TMC-95A and B. Our goal was to

develop simpler and more accessible TMC-95A/B analogues for broad biological evaluation. We hoped to accomplish this by modification of the protocols used in the total synthesis such as to bypass the most difficult transformations. Clearly, the question was whether biological function would be retained by such congeners. If so, valuable proteasome-directed agents might become much more accessible. For instance, we hoped that function could be maintained even with modification of the enamide function at C-8 and the ketoamide section at C-36. A series of analogues was indeed obtained and their inhibition against proteolytic activities of the 20S proteasome was evaluated. We found that some of the simplified analogues retained potent proteasome inhibitory activity.

Results

Design of TMC-95A/B analogues

The four TMC-95s are diastereoisomers with asymmetric centers at C-7 and C-36. TMC-95A and B differ only in the configuration of the methyl group at the C-36 position, but share identical biological activities.[29] This finding suggested to us that the C-36 asymmetric center might have little effect on activity. In contrast, the stereochemistry of the hydroxy group at the C-7 position can influence the activity by up to two orders of magnitude.[29] Recently, it was found that a simplified analogue lacking this hydroxy group is 150 times less potent against CT-L activity of the proteasome than the unmodified molecule.[33] The crystal structure of the 20S proteasome–TMC-95A complex anticipated these *in vitro* findings and provided the structural basis for this new class of noncovalent, reversible inhibitors.[31] The structure suggests that the *cis*-propylene group and the side chain of the asparagine residue, which interact with the S1 and S3 pockets of the proteasome, respectively, provide most of the specific interactions. In addition, the rigid biaryl-linked heterocyclic conformation of TMC-95s appears suitable for optimal binding to the proteasome for entropic reasons. TMC-95A and B block all three active sites but show only moderate selectivity for CT-L activity.[29] These results suggested to us that it might be possible to design potent and subunit-selective inhibitors through optimization of the two groups that bind the S1 and S3 pockets. Since the installation of the enamide group from an alcohol precursor involves multiple steps with low yields, we first chose to modify this position. The allylamide derivatives (**12** and **13**, respectively, Scheme 3) are two analogues that are closely related to TMC-95A and B, but are considerably more accessible. Initially, the two compounds were generated from the side-products of the enamide formation reaction. However, these compounds can be synthesized by directly coupling carboxylic acids **7a,b** and **8a,b** with allylamine, followed by deprotection. The syntheses of these compounds are much more straightforward than those of the parent compounds TMC-95A and B.

In a similar vein, the C-36 asymmetric center on the ketoamide side chain contributes little to potency but necessitates the problematic separation of TMC-95A and B. Therefore, we chose to eliminate this source of stereogenicity. Accordingly, two analogues (**14** and **16**, Scheme 3), each bearing a symmetric ketoamide side chain, were prepared. The corresponding allylamide derivatives (**15** and **17**, Scheme 3) were also generated for evaluation. To further explore the optimal binding groups for the proteasomal S1 pocket, compound **18** (Scheme 3), which has a more flexible propyl group instead of *cis*-propylene at the C-8 position, was synthesized. If this compound were found to be active, we anticipated that an alternative, far more direct and concise route to the target system could be developed. In this way, a simpler amide side chain at C-8 would be installed at an early stage of the synthesis.

We also prepared analogues **19** – **21**, each of which has an alcohol side chain in place of an enamide (Scheme 3). These compounds were designed to markedly reduce the complexity of the synthesis. Specifically, compounds **19** and **20** were generated from a C-11 nitrile analogue of **5**, which is produced as a result of dehydration of the asparagine side chain. Removal of the

silyl group of **6** afforded compound **21**. Both **19** and **21** contain a benzylcarbamate protecting group at the C-14 position. Compound **19** contains a benzyl-protected tyrosine hydroxy group at the C-19 position, while triol **21** has a smaller methyl group at that position. The tyrosine residue of TMC-95s fills the S4 pocket of the proteasome and forms nonpolar interactions with the active sites.[31]

Proteasome inhibition studies

To establish a preliminary structure–activity relationship (SAR) profile of TMC-95A and B, we evaluated the biological activities of our synthetic analogues on purified bovine erythrocyte proteasome. We assessed the rates of proteolytic inactivation achieved by the compounds that fit the profile of slow-binding inhibitors. For these inhibitors, the rates of inhibition, $k_{\text{association}}$ ($k_{\text{obs}}/[I]$; k_{obs} = apparent rate constant for a time-dependent inhibition, $[I]$ = inhibitor concentration) were determined by using fluorogenic peptide substrates and a range of inhibitor concentrations (Table 1). We also determined the inhibition constants (K_{iapp} values) for all the TMC-95 compounds (Table 2) to compare their relative potency. Compounds **12** and **13**, allylamide derivatives of TMC-95A or B, retained full activity and were found to inhibit all proteolytic activities of the proteasome. Compounds **14** and **16**, both containing a non-stereogenic ketoamide side chain at C-14, also exhibit the same potency as the natural products. As expected, compounds **15** and **17**, the allylamide analogues of **14** and **16**, retain potent proteasome inhibitory activity. However, compound **18**, generated by modification of the enamide group of **16** with a propylamide, was found to be ten times less active than **16**. Interestingly, all of the enamide-containing compounds tested (**1**, **2**, **14**, and **16**) behave as slow-binding inhibitors for both CT-L and PGPH activities. These compounds inhibit the chymotrypsin-like activity of the 20S proteasome most potently with $k_{\text{association}}$ values of $190000 - 720000 \text{ M}^{-1} \text{ s}^{-1}$. These rates of inactivation are 4- to 15-fold faster than that of epoxomicin and slightly faster than the rate achieved by the corresponding reversible inhibitor, epoxomicin aldehyde. However, unlike epoxomicin derivatives, none of the inhibitors derived from TMC-95s display slow-binding inhibition against trypsin-like activity.

Triols **19** and **21**, which lack a substituted amide group at the C-8 position, were found to be much less active than the compounds discussed above. The CT-L inhibitory activity of each compound drops more than 1000-fold from those of the natural products. Tetraol **20** is completely inactive. Triol **19**, which contains a benzyl-substituted tyrosine moiety, was found to be three times more active than **21**, which has a smaller methyl-protected tyrosine unit.

Discussion

Current SAR studies suggest that some of the structural elements of TMC-95A and B can be modified to simplify the chemical synthesis but yet retain potent biological activity. The asymmetric center on the ketoamide side chain proves to have little effect on proteasome inhibition and can therefore be eliminated to avoid the problematic separation of diastereoisomers. The results obtained from modifications on the *cis*-enamide side chain, however, are more intriguing. The enamide group can be exchanged with an allylamide without affecting all of the proteasome activities. However, when this group was replaced by a more flexible propylamide, a more than tenfold decrease of all three activities was observed. These findings show that the rigid *cis*-propenyl group can be replaced with a more flexible allyl group without affecting the binding interaction of inhibitors to the proteasome. Reduction of the enamide to a simple alcohol was shown to abolish most of the activities. This result may be explained by the fact that lack of an amide group at that position leads to loss of the favorable hydrogen bond and hydrophobic contacts to the proteasome. Similarly, it has previously been reported that a simple analogue of TMC-95A is 160 times less potent against CT-L activity than TMC-95A, likely as a result of the lack of both the 6,7-dihydroxy groups in the analogue

and the exchange of the *cis*-propenylamide with a propylamide.[33] These results demonstrate the power of chemical synthesis to identify simpler effective proteasome inhibitors derived from natural products. Interestingly, the enamide group appears to be important for slow-binding-inhibitor kinetics.

Given the wide range of cellular processes regulated by the proteasome, controllable and partial blockade of the proteasome functions would be therapeutically beneficial. Reversible and time-limited inhibition of the proteasome can be achieved by using noncovalent inhibitors such as TMC-95s and their synthetic analogues described in this report. Partial inhibition of protein breakdown can be accomplished through rational design of inhibitors that selectively target only one catalytic subunit. All of the proteasome inhibitors currently under clinical investigation are potent inhibitors that act preferentially against CT-L activity. The highly potent TMC-95A and B provide a new lead structure for designing CT-L-activity-selective inhibitors. Numerous studies on proteasomal substrate specificity have been carried out with peptide-based covalent inhibitors.[34–40] These studies highlight the importance of non-P1 interaction in defining and tuning substrate specificity. X-ray crystallography has proven very useful in the determination of the factors dictating the substrate specificity of the proteasome. Crystal structures of the 20S proteasome bound to several different inhibitors have been reported. These inhibitors include peptide aldehyde,[8] lactacystin,[8] epoxomicin,[41] and peptide vinyl sulfones,[42] as well as TMC-95A.[31] Analysis of the TMC-95A structure overlaid with a vinyl sulfone[42] or epoxomicin[31] shows remarkable overlap on both the backbone amides and the P1 and P3 residues. These findings establish the possibility of designing subunit-specific proteasome inhibitors by modification of these two residues of TMC-95A and B. Current investigations clearly indicate that significant changes of potency can be achieved by modification of the P1 *cis*-propenyl group.

Experimental Section

Synthesis of TMC-95A and B analogues

All analogues were synthesized by procedures modified from those previously reported.[32] The full synthesis will be reported elsewhere. Selected physical data for compound 17: ^1H NMR (400 MHz, $[\text{D}_6]\text{acetone}$): δ = 8.47 (d, 1H, J = 8.31 Hz; NH-12), 8.22 (s, 1H; OH-19), 8.18 (s, 1H; NH-22), 7.72 (brs, 1H; NH-26), 7.58 (d, 1H, J = 9.78 Hz; NH-9), 7.51 (d, 1H, J = 7.43 Hz; H-4), 7.43 (d, 1H, J = 2.01 Hz; H-24), 7.33 (dd, 1H, J = 8.85, 1.02 Hz; H-2), 7.32 (d, 1H, J = 6.20 Hz; NH-33), 7.15 (s, 1H; NH-32), 7.00 (dd, 1H, J = 7.68, 7.59 Hz; H-3), 6.87 (d, 1H, J = 8.16 Hz; H-18), 6.80 (dd, 1H, J = 8.15, 2.16 Hz; H-17), 6.46 (s, 1H; NH-32), 5.85 – 5.75 (m, 1H; H-28), 5.67 (s, 1H; OH-6), 5.25 (s, 1H; OH-7), 5.15 (dq, 1H, J = 17.24, 1.70 Hz; H-29), 4.99 (dq, 1H, J = 10.44, 1.62 Hz; H-29), 4.97 – 4.90 (m, 2H; H-14, H-11), 4.43 (dd, 1H, J = 10.42, 3.07 Hz; H-7), 4.09 (t, J = 10.13 Hz; H-8), 3.81 – 3.77 (m, 2H; H-27), 3.54 (m, 1H, J = 6.95 Hz; H-36), 3.22 (dd, 1H, J = 13.91, 2.35 Hz; H-15), 3.08 (dd, 1H, J = 13.89, 4.85 Hz; H-15), 1.14 (d, 3H, J = 6.98 Hz; CH_3), 1.08 (d, 3H, J = 6.96 Hz; CH_3) ppm; ^{13}C NMR (125 MHz, $[\text{D}_6]\text{acetone}$): δ = 202.7, 179.0, 172.5, 172.0, 171.7, 171.5, 160.2, 154.5, 142.0, 135.9, 134.8, 132.4, 131.6, 127.4, 126.7, 124.8, 122.2, 116.8, 115.9, 79.4, 77.8, 55.3, 53.9, 53.7, 51.6, 42.5, 38.6, 38.0, 35.2, 18.4, 18.2 ppm; ESI MS: m/z calcd for $\text{C}_{32}\text{H}_{36}\text{N}_6\text{NaO}_{10}$: 687.3 $[M+\text{Na}]^+$; found: 687.2.

Proteasome inhibition assays

Values of $k_{\text{association}}$ were determined as previously described.[43] Inhibitors were mixed with a fluorogenic peptide substrate and assay buffer (20mM tris(hydroxymethyl) aminomethane (pH 8.0), 0.5mM ethylenediaminetetraacetate, and 0.035% sodium dodecylsulfate (SDS)) in a 96-well plate (SDS was omitted in assays for trypsin-like activity). The chymotrypsin-like, trypsinlike, and PGPH catalytic activities were assayed by using the fluorogenic peptide

substrates Suc-Leu-Leu-Val-Tyr-AMC, Boc-Leu-Leu-Arg-AMC, and Z-Leu-Leu-Glu-AMC (5 μ M; AMC = 7-amino-4-methylcoumarin), respectively. Hydrolysis was initiated by the addition of purified bovine erythrocyte 20S proteasome, and the reaction was followed by observation of fluorescence (360 nm excitation/460 nm detection) with a fluorescence plate reader (Wallac Victor fluorescence plate reader, Perkin – Elmer Life Sciences Inc., Boston MA). Reactions were allowed to proceed for 45 min, and data were collected every 10 s. Fluorescence was quantified as arbitrary units and progression curves were plotted for each reaction as a function of time. Values of $k_{\text{association}}$ ($= k_{\text{observed}}/[I]$) were obtained with the Kaleidograph program by using a nonlinear least-squares fit of the data to the Equation (1):

$$\text{fluorescence} = v_s t + [(v_0 - v_s)/k_{\text{observed}}][1 - \exp(-k_{\text{observed}}t)] \quad (1)$$

where v_0 and v_s are the initial and final velocities, respectively, and k_{observed} is the apparent rate constant for a time-dependent inhibition.[44] The range of inhibitor concentrations tested was chosen so that several half-lives could be observed during the course of the measurement. Values of $k_{\text{association}}$ were determined from three kinetic runs of at least three inhibitor concentrations.

Values of K_{iapp} were determined by using Equation (2):

$$K_{\text{iapp}} = \frac{[I]}{(v_0/v_s) - 1} \quad (2)$$

where v_0 is the rate of enzyme activity in the absence of inhibitor, and v_s is the steady rate of inhibited enzyme activity.[45] In all cases, the substrate concentration was much less than the Michaelis constant. For slow-binding inhibitors, K_{iapp} values were estimated by taking the average final velocity as v_s .

Acknowledgements

This work was supported by the National Institute of Health (Grant no. CA28824). S.L. gratefully acknowledges the US army breast cancer research program for a postdoctoral fellowship (DAMD-17-99-1-9373). C.M.C. gratefully acknowledges support from the National Institutes of Health (Grant no. GM621 20).

References

1. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL. Cell 1994;78:761–771. [PubMed: 8087844]
2. Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL, Rock KL. J. Biol. Chem 1997;272:13437–13445. [PubMed: 9148969]
3. Hershko A, Ciechanover A. Annu. Rev. Biochem 1998;67:425–479. [PubMed: 9759494]
4. Coux O, Tanaka K, Goldberg AL. Annu. Rev. Biochem 1996;65:801–847. [PubMed: 8811196]
5. Baumeister W, Walz J, Zuhl F, Seemuller E. Cell 1998;92:367–380. [PubMed: 9476896]
6. Voges D, Zwickl P, Baumeister W. Annu. Rev. Biochem 1999;68:1015–1068. [PubMed: 10872471]
7. Löwe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Science 1995;268:533–539. [PubMed: 7725097]
8. Groll M, Ditzel L, Löwe J, Stock D, Bochtler M, Bartunik HD, Huber R. Nature 1997;386:463–471. [PubMed: 9087403]
9. Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N, Tsukihara T. Structure 2002;10:609–618. [PubMed: 12015144]
10. Groll M, Heinemeyer W, Jäich S, Bochtler M, Wolf DH, Huber R. Proc. Natl. Acad. Sci. U.S.A 1999;96:10976–10983. [PubMed: 10500111]
11. Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH. J. Biol. Chem 1997;272:25200–25209. [PubMed: 9312134]

12. Bochtler M, Ditzel L, Groll M, Hartmann C, Huber R. *Annu. Rev. Biophys. Biomol. Struct* 1999;28:295–317. [PubMed: 10410804]
13. Ciechanover A. *EMBO J* 1998;17:7151–7160. [PubMed: 9857172]
14. Pamer E, Cresswell P. *Annu. Rev. Immunol* 1998;16:323–358. [PubMed: 9597133]
15. Rock KL, Goldberg AL. *Annu. Rev. Immunol* 1999;17:739–779. [PubMed: 10358773]
16. Niedermann G, Geier E, Lucchiari-Hartz M, Hitziger N, Ramsperger A, Eichmann K. *Immunol. Rev* 1999;172:29–48. [PubMed: 10631935]
17. Klotzel PM. *Nat. Rev. Mol. Cell. Biol* 2001;2:179–187. [PubMed: 11265247]
18. Myung J, Kim KB, Crews CM. *Med. Res. Rev* 2001;21:245–273. [PubMed: 11410931]
19. Kisselev AF, Goldberg AL. *Chem. Biol* 2001;8:739–758. [PubMed: 11514224]
20. Goldberg AL, Rock K. *Nat. Med* 2002;8:338–340. [PubMed: 11927937]
21. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma Y-T, Plamondon L, Stein RL. *Bioorg. Med. Chem. Lett* 1998;8:333–338. [PubMed: 9871680]
22. Bogyo M, McMaster JS, Gaczynska M, Tortorella D, Goldberg AL, Ploegh H. *Proc. Natl. Acad. Sci. U.S.A* 1997;94:6629–6634. [PubMed: 9192616]
23. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. *Science* 1995;268:726–731. [PubMed: 7732382]
24. Meng L, Mohan R, Kwok BHB, Elofsson M, Sin N, Crews CM. *Proc. Natl. Acad. Sci. U.S.A* 1999;96:10403–10408. [PubMed: 10468620]
25. Adams J. *Oncologist* 2002;7:9–16. [PubMed: 11854543]
26. Almond JB, Cohen GM. *Leukemia* 2002;16:433–443. [PubMed: 11960320]
27. Shah SA, Potter MW, Gallery MP. *Surgery* 2002;131:595–560. [PubMed: 12075171]
28. Adams J. *Trends Mol. Med* 2002;8:S49–S54. [PubMed: 11927288]
29. Koguchi Y, Kohno J, Nishio M, Takahashi K, Okuda T, Ohnuki T, Komatsubara S. *J. Antibiot* 2000;53:105–109. [PubMed: 10805568]
30. Kohno J, Koguchi Y, Nishio M, Nakao K, Kuroda M, Shimizu R, Ohnuki T, Komatsubara S. *J. Org. Chem* 2000;65:990–995. [PubMed: 10814045]
31. Groll M, Koguchi Y, Huber R, Kohno J. *J. Mol. Biol* 2001;311:543–548. [PubMed: 11493007]
32. Lin S, Danishefsky SJ. *Angew. Chem* 2002;114:530–533. *Angew. Chem. Int. Ed.* **2002**, 41, 512 – 515
33. Kaiser M, Groll M, Renner C, Huber R, Moroder L. *Angew. Chem* 2002;114:817–820. *Angew. Chem. Int. Ed.* **2002**, 41, 780 – 78
34. Nazif T, Bogyo M. *Proc. Natl. Acad. Sci. U.S.A* 2001;98:2967–2972. [PubMed: 11248015]
35. Elofsson M, Spittgerber U, Myung J, Mohan R, Crews CM. *Chem. Biol* 1999;6:811–822. [PubMed: 10574782]
36. Bogyo M, Shin S, McMaster JS, Ploegh HL. *Chem. Biol* 1998;5:307–320. [PubMed: 9653549]
37. Loidl G, Groll M, Musiol HJ, Ditzel L, Huber R, Moroder L. *Chem. Biol* 1999;6:197–204. [PubMed: 10099130]
38. Kim KB, Myung J, Sin N, Crews CM. *Bioorg. Med. Chem. Lett* 1999;9:3335–3340. [PubMed: 10612595]
39. Harris JL, Alper PB, Li J, Rechsteiner M, Backes BJ. *Chem. Biol* 2001;8:1131–1141. [PubMed: 11755392]
40. Myung J, Kim KB, Lindsten K, Dantuma NP, Crews CM. *Mol. Cell* 2001;7:411–422. [PubMed: 11239469]
41. Groll M, Kim KB, Kairies N, Huber R, Crews CM. *J. Am. Chem. Soc* 2000;122:1237–1238.
42. Groll M, Nazif T, Huber R, Bogyo M. *Chem. Biol* 2002;9:655–662. [PubMed: 12031672]
43. Meng L, Kwok BHB, Sin N, Crews CM. *Cancer Res* 1999;59:2798–2801. [PubMed: 10383134]
44. Morrison JF, Walsh CT. *Adv. Enzymol. Relat. Areas Mol. Biol* 1988;61:201–301. [PubMed: 3281418]
45. McCormack T, Baumeister W, Grenier L, Moomaw C, Plamondon L, Pramanik B, Slaughter C, Soucy F, Stein R, Zühl F, Dick L. *J. Biol. Chem* 1997;272:26103–26109. [PubMed: 9334174]

TMC-95	R ¹	R ²	R ³	R ⁴
A (1)	H	OH	CH ₃	H
B (2)	H	OH	H	CH ₃
C (3)	OH	H	CH ₃	H
D (4)	OH	H	H	CH ₃

Scheme 1.
Structures of TMC-95s.

Scheme 2.

Final steps in the synthesis of TMC-95A and B. Reagents and conditions: a) Pd/C, H₂, EtOH, RT, 19 h; b) (+)-3-methyl-2-oxopentanoic acid, EDC/HOAT, CH₂Cl₂/DMF, RT, 2 h, 0 °C → RT, 2 h, 85% (two steps); c) HF/Py; d) TESOTf, 2,6-lutidine, CH₂Cl₂, 0 °C → RT, 15 h; then NaHCO₃; then citric acid, EtOAc/H₂O; e) Jones reagent, acetone, 0 °C, 2 h; f) **9**, EDC/HOAT, CH₂Cl₂/DMF, RT, 13 h, 33% (four steps); g) o-xylene, 140 °C, 3 d; then H₂O; h) HF/Py, THF/Py; then Me₃SiOMe, 49% (two steps). Bn, benzyl; TIPS, triisopropylsilyl; TES, trimethylsilyl; Tf, trifluoromethanesulfonyl; EDC, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride; HOAT, 1-hydroxyl-7-azabenzotriazole; DMF, N,N-dimethylformamide; THF, tetrahydrofuran; Py, pyridine.

Scheme 3.
Structures of designed TMC-95A analogues.

Table 1Rates of inhibition of proteasome catalytic activities by slow-binding inhibitors.^[a]

	$k_{\text{association}} = k_{\text{observed}} / [I][M^{-1}s^{-1}]$		
	Chymotrypsin-like activity	PGPH activity	Trypsin-like activity
TMC-95A (1)	720000 ± 75000 (4 – 8 nM)	71000 ± 23000 (50 – 200 nM)	N/A ^[b]
TMC-95B (2)	540000 ± 80000 (6 – 10 nM)	44000 ± 12000 (100 – 250 nM)	N/A
14	190000 ± 50000 (30 – 50 nM)	15000 ± 2000 (100 – 250 nM)	N/A
16	520000 ± 120000 (4 – 10 nM)	96000 ± 12000 (40 – 100 nM)	N/A
17	370000 ± 60000 (4 – 10 nM)	79000 ± 16000 (50 – 150 nM)	N/A
Epoxomicin	49000 ± 6000 (40 – 100 nM)	110 ± 20 (10 – 25 μM)	370 ± 90 (1.3 – 10 μM)
Epoxomicin aldehyde	170000 ± 17000 (10 – 25 nM)	3100 ± 1500 (4 – 10 μM)	1100 ± 150 (1.3 – 5 μM)

^[a]The rates of inhibition ($k_{\text{association}}$) of both CT-L and PGPH activities were determined for TMC-95A and B and their slow-binding analogues. The rates of inhibition of all three major proteasome catalytic activities were determined for epoxomicin and epoxomicin aldehyde for comparison. A range of concentrations (given in parenthesis) was used to determine the $k_{\text{association}}$ for inhibition of individual enzymatic activities.

^[b]N/A=not applicable.

Table 2Concentrations required for inhibition of catalytic activities of the proteasome by synthetic inhibitors.^[a]

$$K_{iapp} = [I]/((v_0/v_s) - 1)^{[b]}$$

	Chymotrypsin-like activity	PGPH activity	Trypsin-like activity
TMC-95A	1.1 ± 0.1 nM	29 ± 4 nM	0.81 ± 0.12 μM
TMC-95B	1.7 ± 0.1 nM	23 ± 3 nM	1.1 ± 0.1 μM
12	5.7 ± 0.8 nM	150 ± 20 nM	9.7 ± 3.5 μM
13	6.2 ± 0.4 nM	130 ± 20 nM	9.7 ± 2.4 μM
14	4.9 ± 0.4 nM	63 ± 2 nM	2.6 ± 0.2 μM
15	5.3 ± 0.5 nM	87 ± 12 nM	5.1 ± 0.5 μM
16	1.4 ± 0.1 nM	11 ± 1 nM	0.93 ± 0.11 μM
17	1.9 ± 0.2 nM	23 ± 6 nM	1.2 ± 0.3 μM
18	24 ± 2 nM	110 ± 20 nM	13 ± 2 μM
19	7.0 ± 5.0 μM	5.3 ± 0.6 μM	49 ± 34 μM
20	>100 μM	>100 μM	>100 μM
21	22 ± 10 μM	65 ± 25 μM	>100 μM
Epoxomicin aldehyde	7.0 ± 0.6 nM	2.6 ± 0.1 μM	0.35 ± 0.06 μM

^[a]The concentrations required for inhibition of the three major proteasome catalytic activities were determined for TMC-95A and B, their synthetic analogues, and for epoxomicin aldehyde for comparison.

^[b]The value v_0 is the rate of enzyme activity in the absence of inhibitor, and v_s is the steady rate of inhibited enzyme activity.